glp 1 agonist kidney disease GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal SGLT2 inhibitors and GLP1-RA slow

PD-W: Conceptualization, Methodology, Writing original draft, Writing review & editing

The synthetic form of B12 in shots or injections denotes laboratory-created versions of Vitamin B12, which can mirror the structure and function of naturally occurring B12

This adaptive response can slow weight loss despite maintained exercise habits

Probiotics: Contain beneficial bacteria that may help restore balance to your gut flora

Some real-world cohorts and pooled analyses report greater weight loss among women treated with GLP-1 RAs than among men, though findings are not entirely consistent, and effect sizes vary by agent and population studied (Rivera et al., 2024

This neuroinflammatory cascade also heavily impacts the autonomic nervous system, contributing to the development of dysautonomia and Postural Orthostatic Tachycardia Syndrome (POTS)